|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Active Biotech AB, of Lund, Sweden, selected a candidate drug, ABR-215757, within the systemic lupus erythematosus project (SLE) for clinical development beginning in 2003. SLE is an autoimmune disease with very few available treatments, the company said. The SLE project is included in the company's "competence platform Q."
BioVex Ltd., of Oxford, UK, said the UK's Medicines Control Agency approved the company's application to commence a clinical trial of OncoVEX GM-CSF. The Phase I trial will be undertaken in London, and the safety and biological activity of OncoVEX GM-CSF will be evaluated in a number of solid tumors in 18 patients.
Calcigen Corp., of ...